DDInter1492 DDInter875
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ponatinib {u} (Compound) binds {v} (Gene) RET
Ponatinib {u} (Compound) upregulates {v} (Gene) RAB15
Ponatinib {u} (Compound) downregulates {v} (Gene) ATP6V0B
Ponatinib {u} (Compound) causes {v} (Side Effect) Migraine
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium citrate
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vibrio cholerae CVD 103-HgR strain live antigen
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Tucatinib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ponatinib (Compound) binds RET (Gene)
Ponatinib (Compound) upregulates RAB15 (Gene)
Ponatinib (Compound) downregulates ATP6V0B (Gene)
Ponatinib (Compound) causes Migraine (Side Effect)
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Ponatinib may lead to a major life threatening interaction when taken with Ramucirumab
Ponatinib may lead to a major life threatening interaction when taken with Tucatinib